Sanitas Sitemap|
pl en

Business & Development - Licensing out

Strong position of our company on the market, is among other result of efficient work of highly professional staff of the Business Development Division.
The main objective of the Development Division is launching of new products corresponding to market demands.
This task is realized either by licensing in or internal development in our modern research laboratory department.

Sanitas Group, leader in dermatology in Poland and significant player in CEE region looks for strategic partners to market its dermatology products in West European countries. List of products with availability of dossiers appended.

All dossiers we offer were/will be developed in house, are in CTD format and contain clinical trials. For certain products we are/we will be able to offer also DCP slots.

Sanitas’ dossiers available for licensing out in 2010

API Pharmaceutical form Dossier availability with CT
terbinafine cream available
mometasone solution** available
mometasone cream 10.2010
betamethasone + salicylic acid ointment 11.2010
betamethasone + salicylic acid solution** 11.2010
adapalene cream* 01.2011
adapalene gel* 01.2011

*without clinical trials – CT possible
**bio-waiver

We can also offer Marketing Authorizations/Pending regulatory procedures.
At present we offer:

ACTIVE SUBSTANCE STRENGTH FORM TERRITORY REGISTRATION STATUS
Mycophenolate 500mg TABS Poland, Czech Republic, Slovakia, Romania, Hungary, Latvia, Lithuania MA available
Tacrolimus 0,5 mg, 1mg, 5 mg CAPS Czech Republic* Regulatory procedure pending

* MRP possible out of Czech Republic for Poland, Bulgaria, Slovakia, Romania, Hungary, Latvia, Lithuania.


Contact:
Barbara Olszewska
e-mail: barbara.olszewska@jelfa.com.pl
tel. +48 75 64 33 692